Brief: Cymabay Initiates Affirm, A Phase 3B/4 Study Evaluating The Effect Of Seladelpar On Clinical Outcomes In Patients With Cirrhosis Due To Primary Biliary Cholangitis
21/09/2023 14:33
Sept 21 (Reuters) - Cymabay Therapeutics Inc CBAY.O :
* CYMABAY INITIATES AFFIRM, A PHASE 3B/4 STUDY EVALUATING
THE
EFFECT OF SELADELPAR ON CLINICAL OUTCOMES IN PATIENTS WITH
CIRRHOSIS DUE TO PRIMARY BILIARY CHOLANGITIS
Source text for Eikon: ID:nGNX8Pxyl8
Further company coverage: CBAY.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on CymaBay Therapeutics
See all newsBrief: CymaBay Says EMA Accepted For Review The Marketing Authorization Application For Seladelpar
U.S. RESEARCH ROUNDUP-Bruker Corp, Cymabay Therapeutics, SSR Mining
U.S. RESEARCH ROUNDUP-An2 Therapeutics, Par Technology, Trimble
U.S. STOCKS ON THE MOVE-Perpetua Resources, Nvidia, SiriusXM
U.S. STOCKS ON THE MOVE-Lowe's, Bit Digital Snap